202 related articles for article (PubMed ID: 28125596)
1. Investments in Research and Surveillance Are Needed to Go Beyond Elimination and Stop Transmission of Leishmania in the Indian Subcontinent.
Olliaro PL; Shamsuzzaman TA; Marasini B; Dhariwal AC; Be-Nazir A; Mondal D; Banjara MR; Das P; Sundar S; Rijal S; Arana B; Alvar J; Argaw D; Peeling RW; Kroeger A; Matlashewski G
PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005190. PubMed ID: 28125596
[No Abstract] [Full Text] [Related]
2. Leishmaniasis.
Manson-Bahr PE
Int Rev Trop Med; 1971; 4():123-40. PubMed ID: 4944092
[No Abstract] [Full Text] [Related]
3. Development of Leishmania vaccines in the era of visceral leishmaniasis elimination.
Engwerda CR; Matlashewski G
Trans R Soc Trop Med Hyg; 2015 Jul; 109(7):423-4. PubMed ID: 26048873
[TBL] [Abstract][Full Text] [Related]
4. Recent patents in the treatment and prevention of leishmaniasis.
Shahid SK
Pharm Pat Anal; 2023 Sep; 12(5):237-248. PubMed ID: 38063376
[TBL] [Abstract][Full Text] [Related]
5. Elimination of visceral leishmaniasis on the Indian subcontinent.
Singh OP; Hasker E; Boelaert M; Sundar S
Lancet Infect Dis; 2016 Dec; 16(12):e304-e309. PubMed ID: 27692643
[TBL] [Abstract][Full Text] [Related]
6. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
[TBL] [Abstract][Full Text] [Related]
7. Leishmaniasis: current challenges and prospects for elimination with special focus on the South Asian region.
Karunaweera ND; Ferreira MU
Parasitology; 2018 Apr; 145(4):425-429. PubMed ID: 29642962
[TBL] [Abstract][Full Text] [Related]
8. Visceral leishmaniasis and arsenic: an ancient poison contributing to antimonial treatment failure in the Indian subcontinent?
Perry MR; Wyllie S; Prajapati VK; Feldmann J; Sundar S; Boelaert M; Fairlamb AH
PLoS Negl Trop Dis; 2011 Sep; 5(9):e1227. PubMed ID: 21980542
[No Abstract] [Full Text] [Related]
9. Elimination of visceral leishmaniasis in the Indian subcontinent: a comparison of predictions from three transmission models.
Le Rutte EA; Chapman LAC; Coffeng LE; Jervis S; Hasker EC; Dwivedi S; Karthick M; Das A; Mahapatra T; Chaudhuri I; Boelaert MC; Medley GF; Srikantiah S; Hollingsworth TD; de Vlas SJ
Epidemics; 2017 Mar; 18():67-80. PubMed ID: 28279458
[TBL] [Abstract][Full Text] [Related]
10. An overview of visceral leishmaniasis elimination program in India: a picture imperfect.
Gurunath U; Joshi R; Agrawal A; Shah V
Expert Rev Anti Infect Ther; 2014 Aug; 12(8):929-35. PubMed ID: 24930676
[TBL] [Abstract][Full Text] [Related]
11. [Leishmaniasis: hospital and population-based incidence, and asymptomatic infection. A disease that is still with us].
Bellido-Blasco JB; Arnedo-Pena A; Romeo-García MA; Herrero-Carot C
Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):136-7. PubMed ID: 19254647
[No Abstract] [Full Text] [Related]
12. The economic value of a visceral leishmaniasis vaccine in Bihar state, India.
Lee BY; Bacon KM; Shah M; Kitchen SB; Connor DL; Slayton RB
Am J Trop Med Hyg; 2012 Mar; 86(3):417-25. PubMed ID: 22403311
[TBL] [Abstract][Full Text] [Related]
13. Characterization of Leishmania parasites isolated from provinces of the Islamic Republic of Iran.
Motazedian H; Noamanpoor B; Ardehali S
East Mediterr Health J; 2002; 8(2-3):338-44. PubMed ID: 15339122
[TBL] [Abstract][Full Text] [Related]
14. Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.
Rai K; Cuypers B; Bhattarai NR; Uranw S; Berg M; Ostyn B; Dujardin JC; Rijal S; Vanaerschot M
mBio; 2013 Oct; 4(5):e00611-13. PubMed ID: 24105765
[TBL] [Abstract][Full Text] [Related]
15. Breakthrough in the management of visceral leishmaniasis.
Thakur BB
J Assoc Physicians India; 2003 Jul; 51():649-51. PubMed ID: 14621030
[No Abstract] [Full Text] [Related]
16. Elimination of leishmaniasis (kala-azar) from the Indian subcontinent is technically feasible & operationally achievable.
Bhattacharya SK; Sur D; Sinha PK; Karbwang J
Indian J Med Res; 2006 Mar; 123(3):195-6. PubMed ID: 16778303
[No Abstract] [Full Text] [Related]
17. Comment: current treatment recommendations for leishmaniasis.
Stein ZL
Ann Pharmacother; 1993 Oct; 27(10):1286. PubMed ID: 8251704
[No Abstract] [Full Text] [Related]
18. Visceral Leishmaniasis on the Indian Subcontinent: Modelling the Dynamic Relationship between Vector Control Schemes and Vector Life Cycles.
Poché DM; Grant WE; Wang HH
PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004868. PubMed ID: 27537774
[TBL] [Abstract][Full Text] [Related]
19. Visceral leishmaniasis in the Indian subcontinent: modelling epidemiology and control.
Stauch A; Sarkar RR; Picado A; Ostyn B; Sundar S; Rijal S; Boelaert M; Dujardin JC; Duerr HP
PLoS Negl Trop Dis; 2011 Nov; 5(11):e1405. PubMed ID: 22140589
[TBL] [Abstract][Full Text] [Related]
20. Barriers to treatment for visceral leishmaniasis in hyperendemic areas: India, Bangladesh, Nepal, Brazil and Sudan.
Thornton SJ; Wasan KM; Piecuch A; Lynd LL; Wasan EK
Drug Dev Ind Pharm; 2010 Nov; 36(11):1312-9. PubMed ID: 20545513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
